Regulatory/postmarketing safety summary
Trazodone's Cardiac Safety Profile: What Postmarketing Data Shows
An overview of how QT-interval prolongation and related cardiac rhythm concerns came to be included in trazodone's FDA prescribing information over time.
Published August 8, 2026. Reviewed by our editorial team on August 8, 2026.
Who was studied: General patient population, based on postmarketing adverse event reporting and FDA labeling updates
When trazodone was first approved in 1981, its labeling did not include the level of detail on cardiac rhythm risk that current labeling does. Like many long-marketed drugs, trazodone's prescribing information has been updated over the decades as postmarketing surveillance — voluntary adverse event reports collected after a drug reaches the wider population — identified patterns worth flagging.
Today's FDA-approved Medication Guide specifically lists irregular or fast heartbeat, or fainting related to QT prolongation, among the serious risks patients should discuss with their prescriber. This kind of labeling evolution is a normal part of a drug's regulatory life cycle, not unique to trazodone, and reflects the ongoing pharmacovigilance system working as intended.
Main result: Trazodone's current FDA labeling specifically identifies QT prolongation and associated fast or irregular heartbeat as a risk patients should know about, reflecting accumulated postmarketing reports and pharmacovigilance data gathered since the drug's original 1981 approval.
Limitations: Postmarketing adverse event data can identify safety signals but generally cannot establish precise incidence rates or prove causation as reliably as controlled trials, since reporting is voluntary and influenced by awareness and media attention.
Not medical advice. This summary is educational and does not replace individualized guidance from your prescriber.
